AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30474693 — intervention group
Group type: EXPERIMENTAL
Intervention: KiRA device
Number of subjects: 60
Study 27940324 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20mg per day added to risperidone
Number of subjects: 46
Study 27940324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study 26273138 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Number of subjects: 90
Study 26273138 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 100 mg flurbiprofen axetil by PCA pump
Number of subjects: 90
Study 26273138 — intervention group
Group type: COMPARATOR
Intervention: 10 mL placebo and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Number of subjects: 90
Study 26273138 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative administration of flurbiprofen axetil
Number of subjects: 90
Study 23732551 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with extra-virgin olive oil (EVOO) 1 l/week
Number of subjects: 285
Study 23732551 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with mixed nuts 30 g/day
Number of subjects: 285
Study 23732551 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 285
Study 21690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oseltamivir
Number of subjects: 16
Study 21690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir (infused concurrently with oral oseltamivir)
Number of subjects: 16
Study 21690287 — intervention group
Group type: COMPARATOR
Intervention: Intravenous zanamivir
Number of subjects: 16
Study 19643572 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 1727
Study 19643572 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine maintenance
Number of subjects: 1727
Study 19643572 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1727
Study 17116006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs (9% of subjects in 2004)
Number of subjects: 8827
Study 17116006 — intervention group
Group type: COMPARATOR
Intervention: Population without lipid-lowering drugs
Number of subjects: 8827
Study 17116006 — intervention group
Group type: EXPERIMENTAL
Intervention: Population aged 65-74 years
Number of subjects: 8827
Study 17116006 — intervention group
Group type: COMPARATOR
Intervention: Population with low educational level, BMI >= 25, or smokers
Number of subjects: 8827
Study 17116006 — intervention group
Group type: EXPERIMENTAL
Intervention: Population achieving cholesterol levels below 5.0 mmol L(‐1) in 2004
Number of subjects: 8827
Study 12592544 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 264
Study 12592544 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 264
Study 10788756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drugs
Number of subjects: 0
Study 10788756 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician ratings
Number of subjects: 0
Study 10788756 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study 9303254 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Support Group
Number of subjects: 103
Study 9303254 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional Support Group
Number of subjects: 103
Study 9303254 — intervention group
Group type: COMPARATOR
Intervention: Regular Treatment Group
Number of subjects: 103
Study 7798822 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with home-made spacer
Number of subjects: 20
Study 7798822 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with Nebuhaler
Number of subjects: 20
Study 7798822 — intervention group
Group type: COMPARATOR
Intervention: MDI alone
Number of subjects: 20
Study 3531514 — intervention group
Group type: EXPERIMENTAL
Intervention: +cyanidanol-3
Number of subjects: 26
Study 31392541 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC‐02 (zinc acetate formulation)
Number of subjects: 57
Study 29621201 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) - four cycles of 5 min arm ischemia/5 min reperfusion (n = 19)
Number of subjects: 40
Study 29621201 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (n = 21)
Number of subjects: 40
Study 29621201 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 40
Study 29621201 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 40
Study 26789425 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril + Acetyl Salicylic Acid (ASA)
Number of subjects: 693
Study 26789425 — intervention group
Group type: COMPARATOR
Intervention: Ramipril + Acetyl Salicylic Acid (ASA)
Number of subjects: 693
Study 26789425 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 693
Study 26789425 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 693
Study 25125068 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based PCST program and physiotherapy sessions (PCST + Ex)
Number of subjects: 148
Study 25125068 — intervention group
Group type: COMPARATOR
Intervention: Online educational material (educational control)
Number of subjects: 148
Study 22038842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket feedback card and feedback session
Number of subjects: 111
Study 22038842 — intervention group
Group type: COMPARATOR
Intervention: Usual reminder to provide feedback
Number of subjects: 111
Study 20042768 — intervention group
Group type: EXPERIMENTAL
Intervention: GL2000 (postshock analysis and pulse check)
Number of subjects: 136
Study 20042768 — intervention group
Group type: COMPARATOR
Intervention: GL2005 (immediate CPR resumption)
Number of subjects: 136
Study 20042768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 136
Study 18029476 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 g/d eicosapentanoic acid (EPA) + docosahexanoic acid (DHA) for 6 weeks
Number of subjects: 11
Study 18029476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diets (2 MJ/d) for 4 weeks followed by 4 weeks weight stabilization
Number of subjects: 11
Study 18029476 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (control) for 6 weeks
Number of subjects: 11
Study 15664094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Number of subjects: 52
Study 15664094 — intervention group
Group type: COMPARATOR
Intervention: saline continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Number of subjects: 52
Study 11988438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead awareness intervention
Number of subjects: 0
Study 11988438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 10442843 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline dissemination to all 32 GPs, and a 5-month programme for improvement
Number of subjects: 3950
Study 10442843 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple dissemination)
Number of subjects: 3950
Study 7607280 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon Gamma (rIFN-gamma) administered subcutaneously three times weekly at a dose of 0.05 mg per m2
Number of subjects: 28
Study 7607280 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon Gamma (rIFN-gamma)
Number of subjects: 28
Study 2213948 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin, one dose before procedure and then q 6 h until tube removal)
Number of subjects: 90
Study 2213948 — intervention group
Group type: COMPARATOR
Intervention: Tube thoracostomy alone
Number of subjects: 90
Study 975489 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 74,917 administered from a pressurized aerosol
Number of subjects: 10
Study 975489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31445993 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Media Use
Number of subjects: 25
Study 31445993 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 28902019 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsurface monopolar radiofrequency (SMRF)
Number of subjects: 20
Study 28902019 — intervention group
Group type: COMPARATOR
Intervention: Microfocused ultrasound with visualization (MFU‐V)
Number of subjects: 20
Study 28902019 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsurface monopolar radiofrequency (SMRF) and Microfocused ultrasound with visualization (MFU‐V)
Number of subjects: 20
Study 26160210 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 1713
Study 26160210 — intervention group
Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 1713
Study 22997212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine for 6 weeks
Number of subjects: 5396
Study 22997212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine for 14 weeks
Number of subjects: 5396
Study 22997212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine plus zidovudine for 14 weeks
Number of subjects: 5396
Study 22997212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine for 28 weeks
Number of subjects: 5396
Study 22997212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (time-varying covariate)
Number of subjects: 5396
Study 21495074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 12
Study 21495074 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 18571624 — intervention group
Group type: EXPERIMENTAL
Intervention: Full cognitive intervention (CI)
Number of subjects: 40
Study 18571624 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping alone
Number of subjects: 40
Study 18571624 — intervention group
Group type: EXPERIMENTAL
Intervention: Control alone
Number of subjects: 40
Study 18571624 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction (SI)
Number of subjects: 40
Study 16554455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ciclesonide (800 microg/d)
Number of subjects: 0
Study 16554455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12713767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 827
Study 12713767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study 10722136 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid prophylaxis for tuberculosis infection
Number of subjects: 25
Study 10722136 — intervention group
Group type: COMPARATOR
Intervention: Before treatment
Number of subjects: 25
Study 10722136 — intervention group
Group type: COMPARATOR
Intervention: 1 month into treatment
Number of subjects: 25
Study 10722136 — intervention group
Group type: COMPARATOR
Intervention: At least 1 week after treatment cessation
Number of subjects: 25
Study 8711910 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL protocol
Number of subjects: 149
Study 8711910 — intervention group
Group type: EXPERIMENTAL
Intervention: VEP protocol
Number of subjects: 149
Study 8711910 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL and VEP stereoacuity
Number of subjects: 149
Study 1444522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (1 mg)
Number of subjects: 165
Study 1444522 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin K1 (1 mg)
Number of subjects: 165
Study 1444522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral and intramuscular)
Number of subjects: 165
Study 3969861 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (1 cup)
Number of subjects: 17
Study 3969861 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (2 cups)
Number of subjects: 17
Study 3969861 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 17
Study 30851653 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual exposure (EXP-G; n = 19)
Number of subjects: 40
Study 30851653 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable exposure (EXP-V; n = 21)
Number of subjects: 40
Study 29428960 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma aeruginosa extract (CA-ext) applied twice daily via roll-on applicators
Number of subjects: 30
Study 29428960 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion applied twice daily via roll-on applicators
Number of subjects: 30
Study 28848902 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting cohort
Number of subjects: 115
Study 28848902 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 115
Study 25332466 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified beans (8.8 mg Fe, 1320 mg PA/100 g)
Number of subjects: 22
Study 25332466 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified beans with ∼50% dephytinization
Number of subjects: 22
Study 25332466 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified beans with >95% dephytinization
Number of subjects: 22
Study 25332466 — intervention group
Group type: COMPARATOR
Intervention: Control beans (5.4 mg Fe, 980 mg PA/100 g)
Number of subjects: 22
Study 22348455 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 9
Study 22348455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20973735 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai chi exercise (TCE)
Number of subjects: 0
Study 20973735 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise (CE)
Number of subjects: 0
Study 16602668 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg continuous daily therapy
Number of subjects: 1904
Study 16602668 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg on-demand treatment
Number of subjects: 1904
Study 14597910 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 14
Study 14597910 — intervention group
Group type: COMPARATOR
Intervention: LCPUFA supplemented formula
Number of subjects: 14
Study 11145325 — intervention group
Group type: EXPERIMENTAL
Intervention: Home sleep recording
Number of subjects: 16
Study 11145325 — intervention group
Group type: COMPARATOR
Intervention: Laboratory polysomnography
Number of subjects: 16
Study 9336333 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.66 mg/kg)
Number of subjects: 10
Study 9336333 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0, 0.17, 0.33, 0.66 and 1.33 mg/kg) with ethanol (0 and 1 g/kg)
Number of subjects: 10
Study 9336333 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0 and 0.66 mg/kg) with pentobarbital (0, 1.33 and 4 mg/kg)
Number of subjects: 10
Study 9336333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indomethacin)
Number of subjects: 10
Study 9336333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pentobarbital)
Number of subjects: 10
Study 9336333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ethanol)
Number of subjects: 10
Study 1337362 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of total dietary fiber as modified guar gum
Number of subjects: 11
Study 1337362 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of total dietary fiber as soy polysaccharide
Number of subjects: 11
Study 1337362 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 g of fiber (maltodextrin)
Number of subjects: 11
Study 1337362 — intervention group
Group type: EXPERIMENTAL
Intervention: self-selected diet
Number of subjects: 11
Study 2937825 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 533
Study 2937825 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 533
Study 31370830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable-exposure intervention
Number of subjects: 240
Study 31370830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive feeding intervention
Number of subjects: 240
Study 31370830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (vegetable-exposure + sensitive feeding)
Number of subjects: 240
Study 31370830 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 240
Study 30324933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant with chlorhexidine
Number of subjects: 66
Study 30324933 — intervention group
Group type: COMPARATOR
Intervention: Pit and fissure sealant without chlorhexidine
Number of subjects: 66
Study 27169522 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 23
Study 27169522 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 23
Study 25233346 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid emulsion (ABLE) 15 mg/kg single infusion
Number of subjects: 500
Study 25233346 — intervention group
Group type: COMPARATOR
Intervention: Liposomal formulation (LAmB)
Number of subjects: 500
Study 22842244 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate cement
Number of subjects: 30
Study 22842244 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified GIC
Number of subjects: 30
Study 22842244 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive resin cement
Number of subjects: 30
Study 21164548 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE supplementation (17 g twice daily for 12 weeks)
Number of subjects: 60
Study 21164548 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (CONTROL GROUP)
Number of subjects: 60
Study 18055891 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence summaries appended to discharge letters
Number of subjects: 178
Study 18055891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no evidence summaries)
Number of subjects: 178
Study 18055891 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence summaries
Number of subjects: 178
Study 16567150 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% portion size
Number of subjects: 32
Study 16567150 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% portion size
Number of subjects: 32
Study 16567150 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% portion size
Number of subjects: 32
Study 14593194 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset (0.005, 0.01, 0.03, 0.05, or 0.07 mmol/kg)
Number of subjects: 238
Study 14593194 — intervention group
Group type: COMPARATOR
Intervention: Nonenhanced MR angiography
Number of subjects: 238
Study 14593194 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset
Number of subjects: 238
Study 11081237 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promotion lessons integrated into regular school lessons in the intervention school
Number of subjects: 0
Study 11081237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 0
Study 8935341 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day of terbinafine for 3 months
Number of subjects: 60
Study 8935341 — intervention group
Group type: COMPARATOR
Intervention: 500 mg/day of terbinafine for 7 days during the first week of each month for 3 months
Number of subjects: 60
Study 1287618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF (375 mg twice daily)
Number of subjects: 1138
Study 1287618 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (250 mg three times daily)
Number of subjects: 1138
Study 3896555 — intervention group
Group type: COMPARATOR
Intervention: PAAP (azathioprine/antithymocyte globulin/prednisone)
Number of subjects: 25
Study 3896555 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA (cyclosporine and prednisone)
Number of subjects: 25
Study 29801474 — intervention group
Group type: EXPERIMENTAL
Intervention: HF10 injection every 2 weeks for up to 4 times
Number of subjects: 12
Study 27306560 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan treatment for 4 weeks
Number of subjects: 95
Study 27306560 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypertensive patients
Number of subjects: 95
Study 27306560 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertensive patients
Number of subjects: 95
Study 24149930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G‐GR) 600 mg am/1,200 mg pm
Number of subjects: 600
Study 24149930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G‐GR)
Number of subjects: 600
Study 24149930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 22215656 — intervention group
Group type: EXPERIMENTAL
Intervention: BicaVera solution (bicarbonate/low-GDP PD solution)
Number of subjects: 31
Study 22215656 — intervention group
Group type: COMPARATOR
Intervention: Standard PD fluid (lactate-buffered standard PD fluid)
Number of subjects: 31
Study 22215656 — intervention group
Group type: EXPERIMENTAL
Intervention: BicaVera solution
Number of subjects: 31
Study 22215656 — intervention group
Group type: COMPARATOR
Intervention: Standard PD fluid
Number of subjects: 31
Study 19887019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/d)
Number of subjects: 60
Study 19887019 — intervention group
Group type: COMPARATOR
Intervention: D-serine (2 g/d)
Number of subjects: 60
Study 18036483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical considerations in psychiatric research
Number of subjects: 0
Study 18036483 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of research protocols
Number of subjects: 0
Study 18036483 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled treatment trials
Number of subjects: 0
Study 15759147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of radioiodide
Number of subjects: 114
Study 15759147 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of radioiodide
Number of subjects: 114
Study 11811645 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy plus physiotherapy (SDR+PT)
Number of subjects: 90